Stock screener

GLUE

Conviction 36HealthcareScan · Mon, Aug 10, 2026
GLUE$15.81-0.44%
ResistanceSupportVol 14Insider sell
63 bars
2
2
3
2
2
Vol MA14 1.91M
May 11May 28Jun 16Jul 6Jul 23Aug 10
Monte Rosa Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.monterosatx.com
Price15.81
Change-0.44%
Gap-0.50%
Rel volume1.49×
Avg volume1.64M
Avg $ vol31.04M
SMA 2020.56
SMA 5020.39
SMA 20018.33
Price vs 50-22.45%
Price vs 200-13.72%
MA stackmixed
50/200 cross
Supertrenddown · 20.57
RSI (14)31
MACD hist-0.79
MACD cross
Stoch %K / %D10 / 10
ADX (14)33
+DI / −DI11 / 28
RSI divergence
MACD divergence
ATR %+10.09%
ADR %6.66%
52w high25.31
52w low4.19
From 52w high-37.53%
Above 52w low+277.33%
New 52w highNo
SqueezeOff
Bollinger width68.26%
%B0.16
Donchian pos9.14%
Donchian high25.16
Donchian low14.87
AVWAP (52w high)19.66
vs AVWAP high-19.60%
AVWAP (52w low)16.41
vs AVWAP low-3.63%
OBV trendDown
Chaikin MF (20)0.12
Today vs 20d1.49×
Avg vol (14d)1.91M
Avg vol (20d)1.64M
Avg $ vol (20d)31.04M
Market cap
RS 3m (vs SPY)-25.54%
RS 6m (vs SPY)-30.09%
RS line new highNo
Trend template4/8
Technical rank15.1
1 week+2.80%
1 month-31.38%
3 months-18.46%
6 months-19.13%
1 year+273.76%
YTD+3.27%
P/E-35.11
P/B2.78
P/S10.96
P/FCF-49.31
EPS-2.96
Div yield
ROE-7.93%
ROA-5.59%
Debt/Eq
Current10.58
EV/EBITDA
Gross margin
Net margin-31.23%
Rev growth63.54%
EPS growth46.87%
Price target29.50
Target upside85.59%
Analyst ratingBuy
Institutional107.96%
Ent. value1.27B
Revenue8.97M
Net income-43.4M
Gross profit
Free cash flow-27.5M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out84.48M
Employees161
ListedThu, Jun 24, 2021
Free float
Float %
Short interest
Days to cover
Short volume
Squeeze score
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeD
Conviction36 / 100
Pattern quality
Tech rank15.1 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance25.19
Support14.98
Days since event
Candle confirm
News sentiment

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in GLUE

All disclosures →
No recent disclosed trades by Congress in GLUE. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in GLUE · 2 buys · 8 sells

InsiderSideShares
Warmuth Markus
President & CEO · Common Stock · 2026-07-16
Sell9.5K
Champoux Jennifer
Chief Operating Officer · Stock Option (Right to Buy) · 2026-07-15
Exercise4.35K
Champoux Jennifer
Chief Operating Officer · Common Stock · 2026-07-15
Exercise4.35K
Champoux Jennifer
Chief Operating Officer · Common Stock · 2026-07-15
Sell4.35K
Townson Sharon
Chief Scientific Officer · Common Stock · 2026-07-06
Sell5.6K
Townson Sharon
Chief Scientific Officer · Stock Option (Right to Buy) · 2026-07-06
Exercise6K
Townson Sharon
Chief Scientific Officer · Common Stock · 2026-07-06
Exercise6K
Townson Sharon
Chief Scientific Officer · Common Stock · 2026-07-06
Sell400
Manning Anthony M.
Director · Common Stock · 2026-06-29
Sell10K
Manning Anthony M.
Director · Stock Option (Right to Buy) · 2026-06-29
Exercise10K

SEC filings

EDGAR filings in GLUE · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.